Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott DES program

This article was originally published in The Gray Sheet

Executive Summary

Enrollment in firm's 400-patient, randomized, non-inferiority clinical trial comparing its ZoMaxx drug-eluting stent, which uses Abbott's ABT-578 rapamyacin analogue, to Boston Scientific's Taxus paclitaxel-eluting stent by means of an angiographic endpoint will commence in Q3, VP-Investor Relations John Thomas states during an earnings call July 9. Abbott's Medical Products Group revenue rose 12.8% to $1.05 bil. in the second quarter fueled by strong vascular device and diabetes care sales...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT020524

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel